Survival among clinical stage I–III rectal cancer patients treated with different preoperative treatments: A population-based comparison

Cancer Epidemiology

Volumn 43, Issue , 2016, Pages 35-41

  Joye, Ines ^a,b   Silversmit, Geert ^c   Van Eycken, Elizabeth ^c   Debucquoy, Annelies ^a,c   Vandendael, Tamara ^c   Penninckx, Freddy ^a   Haustermans, Karin ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c Belgian Cancer Registry   (Belgium)

Author keywords

Chemoradiotherapy; Radiotherapy; Rectal neoplasm; Surgery; Survival

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; ARTICLE; BELGIAN; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PREOPERATIVE RADIOTHERAPY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RADICAL RESECTION; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM CARCINOMA; MORTALITY; PATHOLOGY; RECTAL NEOPLASMS; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; NEOPLASM STAGING; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 84978080531     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2016.06.007     Document Type: Article

References (42)

1. [1] Ferlay, J., Soerjomataram, I., Dikshit, R., et al. Cancer incidence and mortality worldwide: sources: methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136 (2015), E359–86.
2. [2] Heald, R.J., Husband, E.M., Ryall, R.D., The mesorectum in rectal cancer surgery −the clue to pelvic recurrence?. Br. J. Surg. 69 (1982), 613–616.
3. [3] Heald, R.J., Ryall, R.D., Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1 (1986), 1479–1482.
4. [4] Enker, W.E., Thaler, H.T., Cranor, M.L., et al. Total mesorectal excision in the operative treatment of carcinoma of the rectum. J. Am. Coll. Surg. 181 (1995), 335–346.
5. [5] Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N. Engl. J. Med. 336 (1997) 980–987.
6. [6] Folkesson, J., Birgisson, H., Pahlman, L., et al. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J. Clin. Oncol. 23 (2005), 5644–5650.
7. [7] Kapiteijn, E., Marijnen, C.A., Nagtegaal, I.D., et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N. Engl. J. Med. 345 (2001), 638–646.
8. [8] van Gijn, W., Marijnen, C.A., Nagtegaal, I.D., et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 12 (2011), 575–582.
9. [9] Roh, M.S., Colangelo, L.H., O'Connell, M.J., et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J. Clin. Oncol. 27 (2009), 5124–5130.
10. [10] Sauer, R., Liersch, T., Merkel, S., et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J. Clin. Oncol. 30 (2012), 1926–1933.
11. [11] Breugom, A.J., Swets, M., Bosset, J.F., et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 16 (2015), 200–207.
12. [12] Bosset, J.F., Calais, G., Mineur, L., et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 15 (2014), 184–190.
13. [13] Kalata, P., Martus, P., Zettl, H., et al. Differences between clinical trial participants and patients in a population-based registry: the German Rectal Cancer Study vs the Rostock Cancer Registry. Dis. Colon Rectum 52 (2009), 425–437.
14. [14] Lewis, J.H., Kilgore, M.L., Goldman, D.P., et al. Participation of patients 65 years of age or older in cancer clinical trials. J. Clin. Oncol. 21 (2003), 1383–1389.
15. [15] Townsley, C.A., Selby, R., Siu, L.L., Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J. Clin. Oncol. 23 (2005), 3112–3124.
16. [16] Den Dulk, M., Krijnen, P., Marijnen, C.A., et al. Improved overall survival for patients with rectal cancer since 1990: the effects of TME surgery and pre-operative radiotherapy. Eur. J. Cancer 44 (2008), 1710–1716.
17. [17] Elliot, A.H., Martling, A., Glimelius, B., Nordenvall, C., Johansson, H., Nilsson, P.J., Preoperative treatment selection in rectal cancer: a population-based cohort study. Eur. J. Surg. Oncol. 40 (2014), 1782–1788.
18. [18] Iversen, L.H., Pedersen, L., Rijs, A., Frijs, S., Laurberg, S., Sørensen, H.T., Population-based study of short- and long-term survival from colorectal cancer in Denmark, 1977–1999. Br. J. Surg. 92 (2005), 873–880.
19. [19] Guren, M.G., Kørner, H., Pfeffer, F., et al. Nationwide improvement of rectal cancer treatment outcomes in Norway. 1993-2010. Acta. Oncol. 54 (2015), 1714–1722.
20. [20] Intermutualistic Agency. http://www.nic-ima.be/ (accessed 08.03.16).
21. [21] Suissa, S., Immortal time bias in pharmaco-epidemiology. Am. J. Epidemiol. 167 (2008), 492–499.
22. [22] Cho, M.M., Morgan, J.W., Knutsen, R., et al. Outcomes of multimodality therapies for patients with stage II or III rectal cancer in California, 1994–2009. Dis. Colon Rectum 56 (2013), 1357–1365.
23. [23] Ke, T.W., Liao, Y.M., Chiang, H.C., et al. Effectiveness of neoadjuvant concurrent chemoradiotherapy versus up-front proctectomy in clinical stage II–III rectal cancer: a population-based study. Asia Pac. J. Clin. Oncol., 2014 (Epub ahead of print).
24. [24] Neugut, A.I., Fleishauer, A.T., Sundararajan, V., et al. Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. J. Clin. Oncol. 20 (2002), 2643–2650.
25. [25] Bujko, K., Nowacki, M.P., Nasierowska-Guttmejer, A., et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br. J. Surg. 93 (2006), 1215–1223.
26. [26] Ngan, S.Y., Burmeister, B., Fisher, R.J., et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: trans-Tasman Radiation Oncology Group trial 01.04. J. Clin. Oncol. 30 (2012), 3827–3833.
27. [27] Martijn, H., Voogd, A.C., van de Poll-Franse, L.V., et al. Improved survival of patients with rectal cancer since 1980: a population-based study. Eur. J. Cancer. 39 (2003), 2073–2079.
28. [28] Tiefenthal, M., Nilsson, P.J., Johansson, R., et al. The effects of short-course preoperative irradiation on local recurrence rate and survival in rectal cancer: a population-based nationwide study. Dis. Colon Rectum 54 (2011), 672–680.
29. [29] Janssen-Heijnen, M.L., Maas, H.A., Houterman, S., Lemmens, V.E., Rutten, H.J., Coebergh, J.W., Comorbidity in older surgical cancer patients: influence on patient care and outcome. Eur. J. Cancer 43 (2007), 2179–2193.
30. [30] Shahir, M.A., Lemmens, V.E., van de Poll-Franse, L.V., Voogd, A.C., Martijn, H., Janssen-Heijnen, M.L., Elderly patients with rectal cancer have a higher risk of treatment-related complications and a poorer prognosis than younger patients: a population-based study. Eur. J. Cancer 42 (2006), 3015–3021.
31. [31] Rutten, H.J., den Dulk, M., Lemmens, V.E., van de Velde, C.J., Marijnen, C.A., Controversies of total mesorectal excision for rectal cancer in elderly patients. Lancet Oncol. 9 (2008), 494–501.
32. [32] Janssen-Heijnen, M.L., Houterman, S., Lemmens, V.E., Louwman, M.W., Maas, H.A., Coebergh, J.W., Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit. Rev. Oncol. Hematol. 55 (2005), 231–240.
33. [33] Pahlman, L., Bohe, M., Cedermark, B., et al. The Swedish rectal cancer registry. Br. J. Surg. 94 (2007), 1285–1292.
34. [34] Anderin, C., Martlin, A., Helborg, H., Holm, T., A population-based study on outcome in relation to the type of resection in low rectal cancer. Dis. Colon Rectum 53 (2010), 753–760.
35. [35] Schmoll, H.J., Van Cutsem, E., Stein, A., et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer a personalized approach to clinical decision making. Ann. Oncol. 23 (2012), 2479–2516.
36. [36] Bosset, J.F., Calais, G., Mineur, L., et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 15 (2014), 184–190.
37. [37] Breugom, A.J., Swets, M., Bosset, J.F., et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 16 (2015), 200–207.
38. [38] F. Penninckx, S. Roels, D. Leonard, et al. Kwaliteit van rectale kankerzorg, fase 1: Een praktijkrichtlijn voor rectale kanker. Good Clinical Practice (GCP). Brussel: Federaal Keniscentrum voor de Gezondheidszorg (KCE); 2007. KCE reports 69A. https://kce.fgov.be/nl/publication/report/kwaliteit-van-rectale-kankerzorg-fase-1-een-praktijkrichtlijn-voor-rectale-kanker.
39. [39] Taylor, F.G., Quirke, P., Heald, R.J., et al. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann. Surg. 253 (2011), 711–719.
40. [40] de Heer, P., de Bruin, E.C., Klein-Kranenbarg, E., et al. Caspase-3 activity predicts local recurrence in rectal cancer. Clin. Cancer Res. 13 (2007), 5810–5815.
41. [41] He, Y., Van't Veer, L.J., Mikolajewska-Hanclich, I., et al. PIK3CA mutations predict local recurrences in rectal cancer patients. Clin. Cancer Res. 15 (2009), 6956–6962.
42. [42] Baik, S.H., Kim, N.K., Lee, Y.C., et al. Prognostic significance of circumferential resection margin following total mesorectal excision and adjuvant chemoradiotherapy in patients with rectal cancer. Ann. Surg. Oncol. 14 (2007), 462–469.